Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Oryzon Genomics's Vafidemstat?
Vafidemstat is a small molecule commercialized by Oryzon Genomics, with a leading Phase II program in Alzheimer's Disease. According to...
Data Insights
Vafidemstat by Oryzon Genomics for Borderline Personality Disorder (BPD): Likelihood of Approval
Vafidemstat is under clinical development by Oryzon Genomics and currently in Phase II for Borderline Personality Disorder (BPD). According to...